Literature DB >> 12044310

Long-term follow-up in patients with a history of (H)ELLP syndrome.

M G van Pampus1, H Wolf, G Mayruhu, P E Treffers, O P Bleker.   

Abstract

OBJECTIVE: To provide long-term follow-up data on women with a history of hemolysis, elevated liver enzymes, and low platelets [(H)ELLP] syndrome regarding the risk of recurrence in subsequent pregnancies and disease in later life.
METHODS: All women admitted to the Academic Medical Centre between January 1984 and January 1996 with (H)ELLP syndrome and a living singleton fetus in utero were included. Women with known preexisting diseases were excluded. The (H)ELLP syndrome was defined as elevated liver enzymes (serum aspartate aminotransferase or serum alanine aminotransferase >or= 50 U/L) and low platelet count (< 100 x 10(9)/L). Those patients with hemolysis (LDH >or= 600 U/L) were classified as HELLP, the remaining ones were classified as ELLP. The participants were asked to fill out a questionnaire regarding their general health and their own obstetric and medical history and that of their first-and second-degree relatives.
RESULTS: One hundred sixteen (94%) of 123 women responded; 4 women had died. The median age of the group was 36.0 years at completion of the questionnaire; the median interval after the index pregnancy was 5.7 years (3-12.9). The incidence of hypertension requiring medical treatment was three times higher than in a reference population of Dutch women between 20 and 40 years old. The need for psychological support was frequent. Thirty-nine patients (34%) refrained from further pregnancies. Twenty-nine percent of the first subsequent pregnancies were complicated by gestational hypertension (GH), but only 2% had (H)ELLP syndrome. Birth weight was, on average, 1385 g higher and gestational age at delivery 5 weeks later in the first subsequent pregnancy irrespective of a recurrence of GH. A family history of cardiovascular disease or preeclampsia was common in the total group; however, this did not influence the recurrence rate. Multiparity, gestational age at delivery <30 weeks, and birth weight <1000 g in the index pregnancy increased the risk of recurrence of GH in the first subsequent pregnancy significantly.
CONCLUSIONS: (H)ELLP syndrome is a severe complication of pregnancy that has not only short-term but also long-term sequelae.

Entities:  

Mesh:

Year:  2001        PMID: 12044310     DOI: 10.1081/PRG-100104168

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  6 in total

Review 1.  Pregnancy-related liver disorders.

Authors:  Ashish Goel; Kapil D Jamwal; Anup Ramachandran; Kunissery A Balasubramanian; Chundamannil E Eapen
Journal:  J Clin Exp Hepatol       Date:  2013-03-16

2.  Inhibition of T-cell activation attenuates hypertension, TNFα, IL-17, and blood-brain barrier permeability in pregnant rats with angiogenic imbalance.

Authors:  Cynthia Bean; Shauna-Kay Spencer; Teylor Bowles; Patrick B Kyle; Jan M Williams; Jacob Gibbens; Kedra Wallace
Journal:  Am J Reprod Immunol       Date:  2016-08-01       Impact factor: 3.886

3.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

4.  Risk for Recurrence of Pre-eclampsia in the Subsequent Pregnancy.

Authors:  Tarakeswari Surapaneni; Vidyavati Patil Bada; C Praveen Kumar Nirmalan
Journal:  J Clin Diagn Res       Date:  2013-12-15

5.  Association of HELLP syndrome with primary antiphospholipid syndrome--a case report.

Authors:  Katalin Veres; Károly Papp; Gabriella Lakos; Edit Szomják; Zoltán Szekanecz; Gyula Szegedi; Pál Soltész
Journal:  Clin Rheumatol       Date:  2007-08-08       Impact factor: 2.980

Review 6.  Corticosteroid Therapy for Management of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count (HELLP) Syndrome: A Meta-Analysis.

Authors:  Minhong Mao; Chen Chen
Journal:  Med Sci Monit       Date:  2015-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.